Vendor Intelligence Report: NUPEPS Peptides

Published 13 Jun 2026. 24-page investigative report on who is behind NUPEPS Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 4 Finnrick lab tests, NUPEPS Peptides has 4 pass / 0 fail — an overall pass rate of 100%. That is a genuinely favorable but narrow signal: the current independent record covers only Retatrutide and Ipamorelin, with Retatrutide the stronger read and Ipamorelin still clean in pass/fail terms. The report cautions against carrying those results into untested catalog items, especially where public COA support is missing, and shows why small-sample ratings move under stricter grading.

Beyond the vials, NUPEPS presents as a very young operation with a thin verifiable footprint. Florida filings point to a newly formed corporation with a sole officer at a Brazilian address, while the U.S. business address resolves to a mailbox environment. The site’s legal pages add friction: a different controller name, a pre-entity update date, and template residue around governing law.

The most serious non-product finding is a separate NUPEPS-branded white-label cryptocurrency portal using facial-KYC components and the peptide company’s legal name. The report also documents Trustpilot and Reviews.io badge claims that resolve to missing profiles, a clustered perfect-score Google review footprint, lab-partner marketing that does not match the COA library, and endotoxin assurances not supported by captured COA language.

Directional buyer read: NUPEPS is more defensible for Retatrutide and Ipamorelin than for the rest of the catalog, based solely on Finnrick’s present testing. The website checkout signal should not be treated as validation of Telegram ordering, crypto payment routes, or any request for biometric identity data.

Inside the full report:

  • Full Finnrick product breakdown, methodology-divergence charts, and rating trajectories for the tested products
  • Florida corporate filing, officer/address trail, registered-agent context, and mailbox-location exhibits
  • Technical capture of portal.nupeps.com, BrokerExchange indicators, S3 branding assets, and facial-KYC components
  • Side-by-side analysis of Vanguard marketing claims, BTLabs COAs, and endotoxin-disclaimer language
  • Trustpilot/Reviews.io verification checks, Google review-cluster analysis, and Telegram complaint exhibits

Risk assessment

  • Parallel cryptocurrency / biometric-KYC portal risk — high: portal.nupeps.com hosts a NUPEPS PEPTIDES CORP-branded BrokerExchange crypto portal using facial-recognition KYC components; the peptide site does not disclose this operation.
  • Telegram payment-fraud risk — high: The official Telegram channel linked from nupeps.com is described in multiple Reddit reports as taking payment and then ghosting buyers.
  • Testing-claim and endotoxin-verification risk — high: NUPEPS advertises Vanguard / LAL endotoxin assurances, while the reviewed COA library showed BTLabs documents and the BPC-157 COA expressly disclaimed endotoxin, microbial, and particulate information.
  • Untested-product coverage risk — medium: Finnrick has tested only Retatrutide and Ipamorelin; other catalog items, including HGH 191AA with no COA found in the field capture, should not inherit those pass results.
  • Review-manipulation and false-endorsement risk — medium: Trustpilot and Reviews.io claims led to 404 pages, and Google reviews were 22/22 five-star in a tight launch-window cluster consistent with astroturfing.